Inositec CEO on 2017 financing plans

December 16, 2016 Christoph Graener

 

Mattias Ivarsson, co-founder and CEO of Inositec, talks to Lucie Ellis, senior writer at Scrip, about the company’s technology and progress since being founded in 2015.
Inositec is developing innovative new drugs using its proprietary Inositune technology to adjust the properties of inositol phosphate analogs. Initially, the company will focus on two areas of high-unmet medical need: calcification disorders and Clostridium difficile infection (CDI).
The company will carry out a series A financing round in 2017 in order to move its drug candidates into clinical studies.

 


  

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Mattias Ivarsson – Co-Founder and CEO, Inositec

 

Previous Article
Deciphera CEO on tackling cancer drug resistance
Deciphera CEO on tackling cancer drug resistance

CEO Michael Taylor talks about Deciphera Pharmaceuticals’ cell-signaling technology and explains the compan...

Next Article
InflaRX CEO highlights pipeline goals
InflaRX CEO highlights pipeline goals

InflaRX is developing highly specific monoclonal antibodies targeting activation products of the complement...